These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 18722785)
1. Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. Berardi R; Verdecchia L; Paolo MD; Giampieri R; Scartozzi M; Pierantoni C; Bianconi M; Mazzanti P; Cascinu S Crit Rev Oncol Hematol; 2009 Mar; 69(3):223-36. PubMed ID: 18722785 [TBL] [Abstract][Full Text] [Related]
2. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. Crawford J J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580 [TBL] [Abstract][Full Text] [Related]
3. Multitargeted inhibitors in lung cancer: new clinical data. Bar J; Herbst RS; Onn A Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor as a target in cancer therapy. Kim ES J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581 [TBL] [Abstract][Full Text] [Related]
5. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Nielsen DL; Andersson M; Kamby C Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049 [TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Engstrom PF; Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548 [TBL] [Abstract][Full Text] [Related]
9. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapies: aiming for the bull's-eye. Gaguski ME ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778 [No Abstract] [Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Medina PJ; Goodin S Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the treatment of lung cancer. Egri G; Takáts A Eur J Surg Oncol; 2006 May; 32(4):385-94. PubMed ID: 16504454 [TBL] [Abstract][Full Text] [Related]
13. Esophageal cancer: current and emerging therapy modalities. Ekman S; Dreilich M; Lennartsson J; Wallner B; Brattström D; Sundbom M; Bergqvist M Expert Rev Anticancer Ther; 2008 Sep; 8(9):1433-48. PubMed ID: 18759695 [TBL] [Abstract][Full Text] [Related]
14. The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction. Chase JL Pharmacotherapy; 2008 Nov; 28(11 Pt 2):17S. PubMed ID: 18980547 [No Abstract] [Full Text] [Related]
15. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use. Prescrire Int; 2009 Feb; 18(99):11. PubMed ID: 19385126 [TBL] [Abstract][Full Text] [Related]